Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns
- Gotham City Research LLC
- 3 days ago
- 1 min read
SUMMARY
Sumitomo Pharma targets 350 billion JPY in iPs revenue, including from Amchepry
The Center for iPS Cell Research & Application (CiRA) is SP’s research partner
CIRA is IPS cells supplier for the Amchepry trials, conducts the trials + research
CiRA is paid by Sumitomo Pharma, with a relationship since 2011.
Sumitomo Pharma is going all-in on CiRA while Takeda recently terminated its 10 year partnership with CiRA.
There are two well documented cases of fraud involving CiRa and its founder Shinya Yamanaka, in 2014 and 2018.
However, we have discovered 8 additional problematic cases, including 1 research paper where the Amchepry trial’s lead investigator is an author
Amchepry depends on the integrity of CiRA, but CiRa is suspect, unreliable.
For the full report:
It’s fascinating how these historical concerns can impact current biotech advancements, reminding us of the importance of transparency in gd research ethics.
It’s fascinating to see how historical concerns shape current practices in biotech, street view. I wonder if exploring more about ethical implications could provide an even deeper understanding of the field.
The combo mechanic is a powerful driver of engagement in rhythm games. By executing precise inputs in succession, players can maintain a scoring streak and tangibly feel their achievements grow with every passing second.
FNF has a way of making a song you failed yesterday feel like a personal challenge today. Load it up again and see if this attempt finally belongs to you.